Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial CONCLUSION: In patients with standard-risk localized EWS, there is no additional benefit from maintenance treatment with … ← Winding Down the Storm: Could Empagliflozin's Ion-Dependent Mechanisms Tackle the Ventricular Arrhythmia Burden in Chronic Chagas Cardiomyopathy? A Critical Analysis of Possible Mechanisms for the Oxygen Effect in Radiation Therapy with FLASH →